Shanghai Junshi Biosciences Co., Ltd. announced that Suzhou Junjing Biomedical Technology Co., Ltd., a company jointly invested by Junshi Biosciences and Wigen Biomedicine Technology (Shanghai) Co., Ltd., has received a notice from the U.S. Food and Drug Administration (the "FDA") concerning the approval of the investigational new drug ("IND") application for XPO1 inhibitor WJ01024 tablets (product code: "JS110") by the FDA.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.18 HKD | -3.33% | -6.74% | -37.35% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.35% | 3.45B | |
-1.62% | 89.22B | |
+1.32% | 40.49B | |
-15.73% | 32.79B | |
+64.13% | 26.23B | |
-21.28% | 14.52B | |
-8.50% | 13.09B | |
-44.07% | 11.6B | |
-13.06% | 11.5B | |
+4.94% | 8.82B |
- Stock Market
- Equities
- 1877 Stock
- News Shanghai Junshi Biosciences Co., Ltd.
- Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)